Daily Newsletter

15 August 2023

Share with colleague
Subscribe

Daily Newsletter

15 August 2023

Share with colleague
Subscribe

Spotlight

Novartis acquires Chinook for $3.2bn to boost kidney disease pipeline

Novartis obtains two Phase III drugs, atrasentan and zigakibart, and Chinook is eligible for an additional $300m in future payments.

Latest news

Botulinum battle heats up with FDA approving Daxxify for cervical dystonia

Daxxify becomes the latest botulinum toxin to make the jump from aesthetics to therapeutics.

15 August 2023

Valneva pushes FDA approval date for chikungunya vaccine

The vaccine is under priority review by the FDA.

15 August 2023

Daiichi Sankyo secures FDA approval for Vanflyta as AML treatment

For Daiichi Sankyo, differentiating Vanflyta from its competitors in the AML space will likely rely on obtaining approval across all three phases of treatment.

15 August 2023

LifeArc invests nearly $10m in Crick Institute’s Africa Scheme

The funding will extend support to the Institute’s Crick Africa Network for five years, supporting African scientists in infectious disease research.

15 August 2023

vTv announces Phase III plans for type 1 diabetes drug cadisegliatin

vTv plans to initiate a Phase III study with an FDA-recommended primary endpoint by the end of 2023.

15 August 2023

AI is essential for the future of drug discovery and development

It is hoped that AI can revolutionise the drug discovery process and significantly reduce the time and cost of getting a drug to market.

15 August 2023

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.